Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncology Reimbursement Experts (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 18, 2007
The Medicare straight jacket: logos over ethos.
Analysis of: Nonpayment for Performance? Medicare's New Reimbursement Rule | content.nejm.org
Author: GLG Expert Contributor
It had to happen. Under any guise a socialized medical schema survives by erecting rigid barriers through rigid rules designed with the efficiency of a cookie-cutter. Performance is determined by a committee absent the individual variations that clinical medicine presents through the variable expression...
October 15, 2007
Failed stomatitis biological dramatiizes simplicity over "super-science".
Analysis of: CuraGen Announces Top-Line Phase II Results on Velafermin | www.pipelinereview.com
Author: GLG Expert Contributor
*Severe stomatitis more than just a cancer therapy experience; common to various virus and medication reactions. *The simple generic "cure" has long been frequent, direct applications of vitamin E: cheap, safe and readily available and it works! *Looking for dramatic specific answers at the sub-cellular...
October 10, 2007
COX 2's Are Not the Future! Same Issues/Same Hosts.
Analysis of: Prexige, Anti-inflammatory Drug, Withdrawn In Canada | www.medicalnewstoday.com
Author: GLG Expert Contributor
ASA was replaced by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as "better tolerated" and as simpler to take until G.I. ulcers and deadly bleeds became a real threat (that later Prilosec-type agents were able to mitigate). An iso-enzyme of NSAIDs (COX 2) proved to have reduced ulcer danger but has...
October 10, 2007
Too much fluoride also means brittle bone.
Analysis of: Some babies get too much fluoride | www.mlive.com
Author: GLG Expert Contributor
Studies have confirmed that too much flouride stimulates brittle bone causing osteomalacia. Prolonged fluoride upsets the balance in bone growth between osteoblasts that build bone and osteoclasts that remove it. The imbalance leads to microfractures of the growing bone, so that mottled teeth are a...
October 9, 2007
Local biologic non-systemic long-term anagesia a potential novel breakthrough.
Analysis of: Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery | www.pipelinereview.com
Author: GLG Expert Contributor
Long-term site analgesia sans systemic agents novel. Short term Phase II study not adequate to answer safety issues in this higher risk elderly host population. FDA should fast track because  of potential risk-benefit potential.
Dea BelaziOctober 3, 2007
WalMart Expansion of $4 generics
Analysis of: Wal-Mart Expands Offerings Of $4 Generic Drugs | online.wsj.com
Author: Dea Belazi, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
WalMarts strategy on expanding $4 generics is not at a loss.  They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit. 
Dea BelaziOctober 3, 2007
Indian Pharmaceutical Manufacturers
Analysis of: Drug discovery hits India | www.icis.com
Author: Dea Belazi, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.
September 20, 2007
Exubera in a European study
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Expert Contributor
European results in a limited number of patients on Exubera for 2-8 years Effectiveness and safety in about a 1/3 of study participants after 8 years
Taral PatelAugust 29, 2007
CMS
Analysis of: New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors | www.medicalnewstoday.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation
August 16, 2007
Subcutaneous injections as treatment for diabetic retinopathy would revolutionize care for these patients
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Expert Contributor
-diabetes and diabetic retinopathy is on the rise due to an increasing epidemic of obesity -diabetic retinopathy is the leading cause of blindness in the United States

Previous Page : 1 2 3 4 5 6 Next31 to 40 of 58

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203